# IBTROZI

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/ibtrozi
Canonical HTML page: https://getyourbrief.com/entity/ibtrozi

## Timeline

- **2026-09-06**: Coverage Highlights Market Divergence — Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
- **2026-09-06**: Coverage Highlights Market Divergence — Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
- **2026-09-03**: Cramer Calls NUVB 'Pure Speculation' — On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
- **2026-09-03**: Cramer Calls NUVB 'Pure Speculation' — On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
- **2026-08**: FDA Grants Fast Track Designation to Safusidenib — Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.
- **2026-08**: FDA Grants Fast Track Designation to Safusidenib — Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.

## Recent coverage (2 stories, network-wide)

### Cramer's 5-Word NUVB Warning as Biotech Surges: 2026 Net Loss Expected
2026-09-07 19:39:28 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Jim Cramer's September 3 'pure speculation' call on Nuvation Bio hits at a moment of momentum: shares rose on FDA Fast Track news and strong early IBTROZI adoption. Yet analysts forecast a full-year 2026 net loss, making the rally a contest between pipeline optionality and burn rate.
Full story: https://getfinancebrief.com/story/nuvation-bio-cramer-pure-spec-net-loss-valuation

### Nuvation Bio's 1 Approved Drug vs Cramer's 5-Word 'Pure Spec' Call
2026-09-07 19:39:18 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Nuvation Bio's experimental brain cancer drug safusidenib won FDA Fast Track in August 2026, but Jim Cramer on CNBC called the surging stock pure speculation. While IBTROZI showed commercial traction as the most-prescribed new lung cancer treatment in early 2026, most value still hinges on late-stage pipeline data.
Full story: https://getbiobrief.com/story/nuvation-bio-cramer-pure-spec-fast-track-safusidenib

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.